Cantor Fitzgerald analyst Jennifer Kim downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight without a price target after the company entered into a merger agreement to be acquired by Roche (RHHBY) at a price of $9.00 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX: